Stay updated on NSCLC Progressed Anti-PD-1 Clinical Trial
Sign up to get notified when there's something new on the NSCLC Progressed Anti-PD-1 Clinical Trial page.
Latest updates to the NSCLC Progressed Anti-PD-1 Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2. This is a minor administrative update with no changes to study content or participant information.SummaryDifference0.0%
- Check16 days agoChange DetectedPublications text was updated to clarify that PubMed entries are automatically filled and may not pertain to the study, and the page revision is updated to v3.3.1.SummaryDifference0.1%
- Check23 days agoChange DetectedRemoved the government funding status notice that appeared at the top of the page. This operational detail does not affect the study data or eligibility information on the ClinicalTrials.gov record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check37 days agoChange DetectedHUDSON umbrella study overview and multiple treatment arms have been added to the Study Details page, including combinations such as Durvalumab with Olaparib, Danvatirsen, Ceralasertib, Vistusertib, Oleclumab, Trastuzumab deruxtecan, and Cediranib. A 'Results Posted' update and expanded study details and locations are also included.SummaryDifference12%
- Check67 days agoChange DetectedVersion update: from v3.0.2 to v3.2.0.SummaryDifference0.1%
- Check68 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.1%
Stay in the know with updates to NSCLC Progressed Anti-PD-1 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NSCLC Progressed Anti-PD-1 Clinical Trial page.